Physician profile
Maheen Haque
NPI 1043452584
$3,036.31
in general payments reported to CMS, 2019-2025
25 companies · $910 in 2025
The $910 reported for 2025 was more than what 75% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $241 · 2020: $235 · 2021: $184 · 2022: $331 · 2023: $584 · 2024: $550 · 2025: $910.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,045.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,044.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $354.41 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $290.34 | 2022-2025 | Envista Mx60 Iol, Ic-8 Apthera Iol, Xiidra |
| Alcon Vision LLC | $280.31 | 2019-2025 | Clareon, Argos, Rocklatan |
| Sun Pharmaceutical Industries INC. | $276.88 | 2019-2025 | Cequa |
| Sight Sciences, INC. | $216.99 | 2025 | Omni Surgical System, Sion Surgical Instrument |
| Rxsight INC | $209.82 | 2022-2025 | Rxsight Injector Handpiece, Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Biotissue Holdings INC. | $178.73 | 2023-2025 | |
| Amgen INC. | $157.89 | 2025 | Tepezza |
| Horizon Therapeutics Plc | $141.08 | 2022 | |
| Allergan, INC. | $123.51 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $113.37 | 2019-2023 | |
| Aerie Pharmaceuticals, INC. | $91.30 | 2020-2021 | |
| Harrow Eye, LLC | $84.44 | 2024-2025 | Vevye |
| Oyster Point Pharma, INC. | $81.65 | 2023 | Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $80.08 | 2024-2025 | Xdemvy |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $65.10 | 2019-2021 | |
| Thea Pharma INC. | $59.94 | 2024-2025 | Iyuzeh |
| Johnson & Johnson Surgical Vision, INC. | $57.74 | 2019-2023 | Tecnis Iol |
| Regeneron Healthcare Solutions, INC. | $32.24 | 2024 | Eylea Hd, Eylea |
| Mallinckrodt Hospital Products INC. | $29.09 | 2020 | |
| Ocular Therapeutix, INC. | $27.83 | 2024 | Dextenza |
| Shire North American Group INC | $24.50 | 2019 | |
| Notal Vision, INC. | $20.88 | 2019 | |
| Carl Zeiss Meditec USA, INC. | $20.62 | 2024 | Iolmaster 700 |
| Tearlab Corp | $17.57 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maheen Haque listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.